Outcomes of Changing Immunosuppressive Therapy after Treatment Failure in Patients with Noninfectious Uveitis

Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behçet Disease

“…Uveitic macular edema is a well-known contributing factor for visual loss in patients with BD[11]. The Standardization of Uveitis Nomenclature (SUN) working group regards CME as a structural complication of uveitis rather than a measure of activity[12].…”

“…The diagnosis of CME was made with the use of fundoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). The presence of intraretinal cystoid edema, central macular thickness (CMT) over 350 µm on OCT, and a minimum of 6 months of follow-up were required for inclusion[11]. In order to abstain from overlapping entities and restrict the treatment to BD-related uveitic macular edema, patients who had neovascularization of the iris, glaucoma, and retinal vascular occlusions and those who had received periocular or intravitreal injections within the past 3 months were excluded.…”

Immunosuppressive Drug Discontinuation in Noninfectious Uveitis From Real-Life Clinical Practice: A Survival Analysis

“…Several studies have been published analyzing in inflammatory ocular diseases the DRs for ISDs [14][15][16][19][20][21][22] (see Supplementary File Discussion for more details). Most studies were focused in the analysis of a single drug [14][15][16]20 , and only three compared the discontinuations among ISDs 21 19 22 .…”

Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis

“…We chose to use the EULAR definition of remission (inactive disease with prednisolone 7.5 mg with/without maintenance treatment) because it is often difficult to achieve complete disease remission without any therapy in systemic diseases. 32,33 In the uveitis literature, the term "remission" is reserved for inactive disease for at least 3 months after discontinuing all treatments, and although this may be possible in conditions such as anterior uveitis, it is acknowledged that in patients with severe uveitis receiving systemic therapy, corticosteroid sparing (prednisolone 10/ 7.5 mg) while maintaining inactive uveitis may be a more appropriate outcome to measure. 24,33 In our study, only 16% of patients eventually stopped prednisolone and maintenance therapy (with no disease activity !3 months after stopping).…”